Jpmorgan Chase & CO Sesen Bio, Inc. Transaction History

Jpmorgan Chase & CO

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	SELL	$0.49 - $0.61 $3,909 - $4,866	-7,978 Reduced 57.8%	5,824 $4,000
Q3 2022 Nov 14, 2022	BUY	$0.0 - $0.93 $0 - $4,349	4,677 Added 51.25%	13,802 $6,000
Q2 2022 Aug 11, 2022	SELL	$0.38 - $0.89 $41,443 - $97,064	-109,061 Reduced 92.28%	9,125 $7,000
Q1 2022 May 11, 2022	BUY	$0.58 - $0.86 $14,249 - $21,128	24,568 Added 26.24%	118,186 $71,000
Q4 2021 Feb 10, 2022	BUY	$0.73 - $1.28 $12,836 - $22,507	17,584 Added 23.13%	93,618 $77,000
Q3 2021 Nov 12, 2021	BUY	$0.77 - $4.91 $58,546 - $373,326	76,034 New	76,034 $60,000

Ticker SESN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 201,702,000
Market Cap $127M
Description
Sesen Bio, Inc., a late-stage clinical company, focuses on designing, engineering, developing, and commercializing targeted fusion protein therapeutics (TFPTs) for the treatment patients with cancer. Its lead product candidates include Vicineum, a locally-administered targeted fusion protein that is in Phase III clinical trials for the treatment...

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

Stay updated on Jpmorgan Chase & CO with notifications on news.